News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Distinguished Cannabis Industry Expert Joins Phase 4 Services as VP of Business Development

Phase 4 Services

Hemp and cannabis testing laboratory management and consulting firm Phase 4 Services has tapped Jonathan Wani of MCR Labs as their latest VP addition and leader of the group’s business development consulting team. As VP of Business Development, Wani will draw on his 7 years of experience in the cannabis testing space as well as more than a decade’s worth of knowledge and connections gathered advocating for medical marijuana and fighting against cannabis prohibition. He will assist Phase 4 clients with establishing footholds in new and expanding markets. “We knew how to figure out the science and chemistry we needed to start MCR Labs, but Jon was the x-factor that got us real traction in the industry,” said Michael Kahn, founder and CEO of MCR Labs, a cannabis testing lab operating in several legal cannabis markets. “He knew about the products we’d be testing, and he could talk the talk with all the growers we needed to be testing for.” Wani is known in the cannabis space for his awareness of industry shifts and knowledge of production processes and product lineages. His connections with influencers, cannabis cup organizers, and prominent growers and extractors have enabled him to establish strong relationships with some of the largest multistate operators in the expanding cannabis industry. He is also a sought-after speaker for educational and industry-focused events. Adding Wani to the team allows Phase 4 Services to offer their clients valuable industry insights and networking opportunities that guide strategy implementation and facilitate expansion initiatives. About Phase 4 Services: Phase 4 Services is a scientific consulting and laboratory management firm dedicated to growing, supporting, and enhancing hemp and cannabis testing laboratories. Founded by experts in analytical testing, pharmaceutical chemistry, business administration, and development strategy, our team is equipped with the knowledge and experience necessary to ensure partner laboratories are successful in their pursuit of advancing public health and safety for cannabis patients and consumers. For more information visit http://phase4services.com. Contact Details Phase 4 Services Joe Crinkley +1 857-230-0839 PR@phase4services.com Company Website https://phase4services.com/

July 27, 2021 10:51 AM Eastern Daylight Time

Article thumbnail News Release

AS&K Group Sets Science Based Targets for Emissions Reduction

AS&K Group

Medical communications group AS&K has set ambitious emissions reduction goals using the Science Based Target initiative’s (SBTi) framework for SMEs. This global organization provides companies with a clearly defined pathway to future-proof growth by specifying how much and how quickly they need to reduce their greenhouse gas (GHG) emissions. By joining more than 1,000 visionary businesses from all industries including major pharmaceutical companies, AS&K is leading the way in the medical communication sector in this important worldwide effort to tackle the climate crisis. AS&K has set a group-wide goal of 50% reduction in GHG emissions, which is in line with the most stringent goal of the Paris Agreement to keep global warming to 1.5C and prevent the most damaging effects of climate change. “AS&K understands the urgent need for companies to take action to address the climate crisis. We’re absolutely committed to doing all that we can, and will also work with our clients to reduce the climate impact of their medical communication activities,” said Simon Gee, AS&K Agency Head. As well as reducing emissions, AS&K is aiming to become net zero before 2030 by supporting programs that mitigate the effects of their remaining emissions. “The climate crisis is one of the most important issues of our times and we’re passionate about taking meaningful steps to reduce our carbon footprint. Joining the SBTi and setting emissions reduction goals is a critical first step in getting to net-zero as soon as we can,” added Katherine Vik, Senior Digital Project Manager and Chair of AS&K’s Climate Committee. “We are also running a number of workstreams to help our clients reduce the environmental impact of their medical communications.” More information about AS&K’s commitment is available on the SBTi website. About AS&K Group: The AS&K Group is an independently owned group of medical communications agencies who collaborate with leading pharmaceutical and medical device companies. As strategic partners and subject matter experts, the AS&K Group transforms complex scientific information into compelling programs that inform and educate healthcare professionals. The AS&K Group comprises three innovative companies: Remedica, AS&K Communications and The Corpus. Follow our journey on Twitter @asandkgroup and Linkedin Contact Details AS&K Group Alana Zdinak +44 7766 706656 alana.zdinak@asandk.com Remedica Alejandro Potes +44 20 7428 2996 alejandro.potes@remedica.com Company Website https://asandk.com/

July 27, 2021 10:18 AM Eastern Daylight Time

Article thumbnail News Release

NextFerm Technologies Announces First Commercial Purchase Order of ProteVin™ in the US

NextFerm Technologies Ltd.

NextFerm Technologies (TASE:NXFR), a food-tech company developing ProteVin™, a vegan, yeast-based, non-GMO protein alternative and other innovative yeast-based nutrients, announced that it has received first commercial Purchase Order for ProteVin™ from a US customer. The Purchase Order, of $70K, was received from PrimaLife Nutrition, a new brand aiming to be the first to launch a vegan sports protein powder based on ProteVin™ in the US and to provide athletes for the first time with a vegan formula with nutritional value similar to whey protein powder and excellent taste. This Purchase Order marks the achievement of a second out of three milestones set by the company for 2021 according to its strategic plan for commercialization of ProteVin™ in 2022. In light of the progress with a number of potential customers, the company expects to receive additional Purchase Orders for ProteVin™ by the end of 2021. On the production side, the company is currently in dialogues with several potential subcontractors in the food industry and is progressing as planned towards engagement with a subcontractor by the end of 2021. Boaz Noy, Chief Executive Officer of NextFerm, said, “ We are happy to announce of the receipt of first commercial Purchase Order for Protevin™ by PrimaLife Nutrition LLC, an emerging vegan-based sports’ nutrition brand from Florida. This order represents the achievement of yet another important milestone for commercialization Protevin™ by 2022, earlier than anticipated, and serves as a great vote of confidence in our technology and the benefits it has to the end consumers. In light of our progress with other potential customers, we expect to receive additional orders in the coming months as we advance towards engagement with manufacturing sub-contractor before the end of this year.” Walter Ross, Owner of PrimaLife Nutrition, said, “ I intend to promote Protevin™ through multiple channels, including digital campaigns as well as traditional brick and mortar stores. As someone who has received education and certifications in Sports Nutrition and Personal Training, I see great value in Protevin™ due to its high degree of sustainability and complete amino acid profile. Having a single-ingredient, environmentally friendly, and complete protein, with digestibility comparable to whey, makes Protevin™ a perfect solution. I also believe its flavor-neutral profile and a shelf-life similar to current market categories make implementing the technology and creating a demand feasible,” Mr. Ross concluded. About NextFerm Technologies NextFerm Technologies, traded on the Tel Aviv Stock Exchange (TASE:NXFR) is a food-tech company engaged in the research, development, manufacturing and marketing of innovative, functional and vegan yeast-derived, non-GMO protein alternatives for various applications in the food and food supplement markets and the growing market for animal-derived protein alternatives. NextFerm's flagship product is ProteVin™, a vegan, yeast-derived protein alternative with nutritional value that is similar to animal-derived protein and a neutral flavor, with no aftertastes that are typical of plant-based protein. ProteVin™ is designed for a variety of categories in the alternative protein market, which is estimated at $13 billion, with an annual growth rate of 10%, including milk and dairy substitutes, meat substitutes and additional categories such as infant nutrition, adult nutrition, and sports nutrition. NextFerm is gearing up for commercialization of the product in the US in 2022. Another product currently being sold is Astaferm®, an innovative astaxanthin-based antioxidant derived from yeast that has been sold in the US since the end of 2020 through well-established and leading brands in the food supplement market in the US. The company has additional products which have been licensed to Lallemand, a global giant focused on yeast. For more information, visit the NextFerm website at: www.nextferm.com Legal Notice Regarding Forward-Looking Statements This announcement also includes forecasts, projections, assessments, estimates and other information which refer to future events and matters, the realization of which is uncertain and not exclusively under the Company’s control (forward-looking information). The main facts and data used to support this information are facts and data regarding the current position of the Company and its businesses (including the scope of sales and levels of profitability, manpower, commercial engagements and more), facts and data regarding the current global position of the Company’s operating segments (including industry-specific financial developments, environmental regulatory developments, the competitive environment, technological developments, the reinsurance market and more), and macro-economic facts and data (including the economic situation both in Israel and around the world, yields in the capital markets, social and state developments and more), all as known by the Company when publishing this announcement. The forward-looking information included above in this announcement is significantly based upon, in addition to the existing information held by the Company, on the Company’s current assessments and expectations of future developments vis-a-vis each one of the aforementioned parameters, and the interconnectedness of each one of these developments. The Company has no certainty that its forecasts and assessments will indeed eventuate, and the Company’s operating results may be materially different than the results assessed or implicit based on that set forth above, inter alia, as a result of a change in any of the aforementioned factors. Contact Details Nextferm Technologies Ltd. Yossi Ohana - Chief Financial Officer +972 54-771-5893 yossio@nextferm.com Investor and Media contact Meirav Gomeh-Bauer +972 54-476-4979 meirav@bauerg.com Company Website https://www.nextferm.com/

July 26, 2021 10:03 AM Eastern Daylight Time

Article thumbnail News Release

Elsevier partners with American College of Medical Genetics and Genomics to publish Genetics in Medicine

Elsevier

The American College of Medical Genetics and Genomics (ACMG), the only nationally recognized US medical professional organization solely dedicated to improving health through the practice of medical genetics and genomics, and Elsevier, a global leader in research publishing and information analytics, are delighted to announce a new partnership to publish ACMG’s official journal, Genetics in Medicine ( GIM ). The journal will also offer authors an open access option and will be hosted on Elsevier’s leading online platform, ScienceDirect, beginning January 2022. ACMG was founded in 1991 and currently has a membership of more than 2,300 clinical and laboratory geneticists, genetic counselors, and other healthcare professionals. ACMG’s decision to partner with Elsevier directly supports its mission to improve personal and public health through the clinical and laboratory practice of medical genetics; advocacy, education, and clinical research programs; and the safe and effective integration of genetics and genomics into all of medicine and healthcare. ACMG Chief Executive Officer Maximilian Muenke, MD, FACMG, said: “We welcome Elsevier as our new publisher and look forward to taking advantage of their publishing expertise and commitment to innovation, as we continue to increase the visibility and influence of Genetics in Medicine together. “Medical, scientific and research professionals in a broad range of specialties turn to ACMG’s official journal for the very latest research and clinical practice in medical and laboratory genetics. Together with our new trusted partner, we will continue to publish cutting edge original research, appropriate reviews, as well as recommendations and guidelines from our ACMG committees.” Medical genetics is becoming increasingly important in the wider medical practice. GIM ’s eminent editorial board under the continued leadership of Editor-in-Chief Robert D. Steiner, MD, FAAP, FACMG, ensures that this high quality, peer-reviewed journal will continue to be an authoritative resource for the dissemination of medical genetic knowledge to providers both within and outside of the genetics community. “We are tremendously excited for the opportunity to partner with Elsevier to publish ACMG’s official journal, Genetics in Medicine beginning in 2022,” said Dr. Steiner. “Elsevier is one of the worldwide premier publishers of journals devoted to biomedical research. It is clear from our early interactions with Elsevier staff and leadership that this will be a partnership in the truest sense of the word. “I have every confidence that support from the Elsevier team will foster even greater success in our ongoing efforts to publish novel, transformative, and clinically relevant genetic and genomic science. On behalf of GIM ’s editors, editorial staff, reviewers, and authors, I want to welcome our trusted and capable new partner, Elsevier.” Elsevier is committed to the continuity of the journal’s rigorous editorial process and accessibility of content, and further solidifying GIM ’s reputation for publishing papers based on the quality of the science and its substantial contributions to advancements in the field. “We are delighted ACMG has selected Elsevier as its publishing partner. By combining their expertise in medical genetics with Elsevier’s outstanding author, editor, and reader outcomes, we will ensure the best possible support for ACMG’s mission and community,” stated Neil Appleton, Senior Vice President, Society Business Development, Elsevier. About Genetics in Medicine ( GIM ) Genetics in Medicine is the official journal of the American College of Medical Genetics and Genomics. The mission of the journal is to enhance the knowledge, understanding, and practice of medical genetics and genomics through publications in clinical and laboratory genetics and genomics, including ethical, legal, and social issues as well as public health. As genetics and genomics continue to increase in importance and relevance in medical practice, the journal will continue to be an accessible and authoritative resource for the dissemination of medical genetic knowledge to all medical providers through appropriate reviews, discussions, commentaries, recommendations, standards, and guidelines. About American College of Medical Genetics and Genomics (ACMG) Founded in 1991, the American College of Medical Genetics and Genomics (ACMG) is the only nationally recognized medical professional organization solely dedicated to improving health through the practice of medical genetics and genomics, and the only medical specialty society in the US that represents the full spectrum of medical genetics disciplines in a single organization. The ACMG is the largest membership organization specifically for medical geneticists, providing education, resources and a voice for more than 2,300 clinical and laboratory geneticists, genetic counselors and other healthcare professionals, nearly 80 percent of whom are board certified in the medical genetics specialties. ACMG’s mission is to improve health through the clinical and laboratory practice of medical genetics as well as through advocacy, education and clinical research, and to guide the safe and effective integration of genetics and genomics into all of medicine and healthcare, resulting in improved personal and public health. www.acmg.net About the Editor-in-Chief Robert D. Steiner, MD, FAAP, FACMG, served as a section editor for GIM beginning in 2006, became deputy editor in 2011, and took charge as Editor-in-Chief starting in 2019. He is Professor (Clinical) of Pediatrics at the University of Wisconsin (UW) School of Medicine and Public Health and chief medical officer for PreventionGenetics. He is also medical consultant for the Newborn Screening Program for the Wisconsin Department of Health Services. After obtaining his MD from UW, he completed a residency in pediatrics at The University of Cincinnati/Cincinnati Children’s Hospital and Medical Center. Following residency, Dr. Steiner trained in medical genetics at The University of Washington/Seattle Children’s Hospital and Regional Medical Center. He is board certified in Pediatrics, Clinical Genetics and Clinical Biochemical Genetics. About Elsevier and society partnerships Elsevier has long partnership records with over 600 learned scientific societies, working in partnership to realize societies’ missions and inspire and support their communities. Our own mission is to help deliver outstanding publishing outcomes, widespread use of research, reliable finances, embracing Open Science and Open Access and championing you and your community. www.elsevier.com/societies About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Contact Details Kathy Moran, Senior Director, Communications and Public Relations American College of Medical Genetics and Genomics kmoran@acmg.net Jonathan Davis, Elsevier Communications, Europe j.davis.1@elsevier.com newsroom@elsevier.com

July 26, 2021 09:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

Transplant equity efforts presented to the National Academies of Sciences, Engineering and Medicine

United Network for Organ Sharing

Increasing equity in the national transplant system was the focus of remarks made recently by United Network for Organ Sharing (UNOS) CEO Brian Shepard and Board President-Elect Jerry McCauley, M.D. at a meeting organized by the National Academies of Sciences, Engineering and Medicine. Shepard and McCauley both spoke before the Committee on A Fairer and More Equitable, Cost-Effective, and Transparent System of Donor Organ Procurement, Allocation, and Distribution about the ongoing work UNOS is doing to ensure every transplant candidate has equitable access to life-saving organs through policy making and data. “UNOS is acutely attuned to issues of equity,” said Shepard, “Committees of experts from professional and patient communities review the anticipated impact on equity of new policies before they are approved, and once implemented, routinely monitor data to ensure that the policies have their intended effects and are not disadvantaging any candidates.” McCauley, chief of nephrology at Jefferson University Hospitals in Philadelphia, spoke in particular about the efforts of Organ Procurement and Transplantation Network’s Minority Affairs Committee (MAC), and their charge to monitor, identify, and help correct racial and ethnic disparities in transplantation. UNOS is the mission-driven nonprofit organization that serves as the OPTN under federal contract. “As [organ allocation] policies are being developed, those policies come to the [Minority Affairs Committee] and we get to look at whether or not there are obvious disparities,” McCauley said. “These things are being vetted before the policy is rolled out.” He also referenced how the committee has championed changes to kidney allocation policy in recent years, leading to policies that, once on the waiting list, have made access for Black kidney transplant candidates equitable. A wide variety of this data is publicly available on the UNOS and OPTN websites. Additionally, UNOS researchers developed and launched the Equity in Access to Transplant Dashboard, which allows users to explore how different factors impact waitlist candidates. According to the dashboard, where a patient is listed has the highest impact on access. In his remarks, Shepard went on to stress the need to expand equitable access, and emphasized UNOS’ commitment to ongoing improvement as the high-performing, mission-driven non-profit serving as the nation’s transplant system. “The ultimate form of equity that is UNOS’ goal and the goal of the entire organ donation and transplant community, is to provide a transplant for every single patient that needs one,” he said. “We are looking for continuous improvement of what is already the world’s best donation and transplant system.” Learn more about our ongoing equity work: Workgroup to examine use of race-based adjustment to kidney calculation Data dashboard monitors equity in access to transplant The road to racial equity in kidney transplantation New kidney and pancreas allocation system will increase equity ### About United Network for Organ Sharing United Network for Organ Sharing (UNOS) is the mission-driven nonprofit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

July 22, 2021 01:18 PM Eastern Daylight Time

Image
Article thumbnail News Release

Vietnam Government supports T&T Group in purchase of 40 million Sputnik V vaccine doses

T&T Group

HANOI, VIETNAM - Media OutReach - 22 July 2021 - On July 12, the Government of Vietnam issued Resolution No. 73/NQ-CP allowing T&T Group to purchase Sputnik V vaccines from the Russian Federation without using funds from the State budget or Vietnam's COVID-19 Vaccine Fund. The Government's resolution stated that, at the request of the vaccine manufacturer, the Government agreed to a proposal from the Ministry of Health to sign an agreement that relinquishes liability for the use of the Sputnik V vaccine. The agreement is similar to the agreement signed by the Ministry of Health when Vietnam Vaccine Joint Stock Company (VNVC) purchased a supply of the BNT162 vaccine from Pfizer and AZD1222 vaccine produced by AstraZeneca. Vietnamese authorities will be responsible for licensing import, inspection, and quality control of vaccines, organize free injection of all 40 million doses of vaccines mentioned above under regulations. Implementing the Government's resolution, the Ministry of Health sent an official dispatch to the Russian Direct Investment Fund (RDIF) to introduce them to the T&T Group to negotiate to buy 40 million doses of the Sputnik V vaccine. In the document, the Ministry of Health proposed RDIF give favourable conditions to T&T Group to purchase the Sputnik V vaccine in July 2021 to meet the urgent need to stem the spread of COVID-19 in Vietnam. Mr Do Quang Hien, Chairman and General Director of T&T Group, shared: "Being socially responsible and with the desire to bring a safer and better life to the Vietnamese people, we were very honoured and proud when the Government agreed to allow us to negotiate to buy 40 million doses of Sputnik V vaccine from the Russian Federation.” "With 28 years of experience, a strong reputation, and great financial potential, along with many member units that have been operating in the field of health and pharmaceuticals for many years, T&T Group will make every effort to implement this great mission successfully.” “At the same time, we look forward to a long-term, strategic relationship with the world's leading pharmaceutical corporations not only in importing vaccines but also in receiving and transferring vaccine production technology to Vietnam. " Established in 1993, T&T Group is one of the leading private multi-sector economic groups in Vietnam. It has over 80,000 employees working in Vietnam and representative offices in many countries such as the US, Russia, Germany, and Australia. Currently, T&T Group operates in several key sectors: Finance and investment, real estate, industry and trade, logistics, traffic infrastructure, seaports, energy, environment and minerals, agriculture, forestry and fishery, health, education, and sports. With outstanding business achievements and contributions to the community, T&T Group has been honoured twice to be awarded the First-class Labor Medal and many other noble awards. Mr Do Quang Hien was also honoured to receive the First Class Labor Medal in 2019 awarded by the President of the Socialist Republic of Vietnam and the Asian Entrepreneur Award in 2017 awarded by Enterprise Asia - Asia's leading NGO. Since the outbreak of the COVID-19 pandemic in early 2020, T&T Group and its member units have donated over $21.7 million for COVID-19 prevention and control activities in Vietnam. #T&TGroup Contact Details International Trade and Investment Promotion Department Ms. Nguyen Van Huong huongnv@ttgroup.com.vn

July 22, 2021 08:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

On One-Year Anniversary of ATLAS® Launch, 40 Percent of US Population Will Soon be in a State with Access to Free, Transparent Information on Addiction Treatment Quality

Shatterproof

Nationally, substance use disorder is on the rise and fatal drug overdoses have reached an all-time high, with over 90,000 deaths occurring in the 12 months ending in December 2020, according to recent Centers for Disease Control and Prevention (CDC) data. To help those in need, Shatterproof, a nonprofit organization dedicated to reversing the addiction crisis in the United States, is expanding and enhancing its free tool, ATLAS ®, to connect individuals with high-quality, appropriate addiction treatment throughout California. ATLAS was launched one year ago today, and is currently available in Delaware, Louisiana, Massachusetts, New York, North Carolina, and West Virginia. Shatterproof announced last month that ATLAS is also expanding its reach to Florida, New Jersey, Oklahoma, and Pennsylvania, empowering 28 percent of the US population to find evidence-based treatment within their state next spring. Once implemented next year in California, ATLAS will be available to just over 40% of the US population – a monumental accomplishment within just one year of the platform’s launch. ATLAS will be available to California residents in Winter 2022. “Access to high quality, evidence-based care for substance use disorder is part of our strategic vision for behavioral health care in California,” says Kelly Pfeifer, M.D., Deputy Director, Behavioral Health, California Department of Health Care Services. “We are excited to join the ranks of states across the country that are partnering with Shatterproof to use ATLAS to help combat the addiction crisis that affects far too many individuals and families.” “It is now more critical than ever, given the profound uptick in fatal overdoses and the impact that COVID-19 has had on addiction and mental health, that people are able to access a trusted, free resource when searching for quality substance use disorder treatment for themselves or a loved one,” says Gary Mendell, Founder and CEO, Shatterproof. “Trust is everything. We know that it can be a confusing, scary time when someone is seeking help, and we want to ensure that the information available to find quality care is trusted, unbiased, and meets the person’s needs.” ATLAS is the only platform that measures the quality of addiction treatment and makes this information publicly available. This free tool identifies addiction treatment providers’ use of evidence-based best practices and displays this information to support those in need and their loved ones in navigating to appropriate, quality care. Individuals can search for and compare treatment options using criteria that are important to them – such as location, particular services offered, and insurance accepted. ATLAS also allows patients (or their family members acting as a proxy) to provide feedback on their treatment experience. The platform lists all authorized treatment providers in a state. The current ATLAS platform has many unique features: Facilities’ use of best practices measured against Shatterproof National Principles of Care, which are evidence-based standards derived from the landmark 2016 Surgeon General’s Report on Addiction as well as subject matter and other clinical experts; Display of feedback from patients and family members, updated daily; An Addiction Treatment Needs Assessment, created in collaboration with the subject matter expertise of the American Society of Addiction Medicine (ASAM) and OpenBeds, to help guide the search based on an individual’s needs and severity; Ability to search and filter using criteria such as location, services offered, and insurance provider. The ATLAS platform, www.TreatmentATLAS.org has seen more than 110,000 website visits since launch in July 2020, was successfully implemented in 6 states, now expanding to 5 more with data from more than 1200 facilities included, and will be updated over the coming months to enhance the experience of those seeking treatment. ATLAS 2021 enhancements include: All content available in Spanish. Ability to search for facilities by name. Improved display of insurance information Integration of state resources into ATLAS Updated educational content to increase readability. In addition, the platform also offers secure access to critical data for state policymakers, providers, and insurance payers to further drive improvements to the addiction treatment space, fueled by increased accountability and transparency: Addiction treatment providers can compare their quality data to that of their peers and use these metrics to inform internal quality improvement efforts. Payers can use metrics to assess the performance of providers to more easily align financial incentives to support quality care over quantity. State policymakers can use the data to better direct policy, assess changes, and disseminate resources such as technical assistance to support providers. When the platform launches in Florida, New Jersey, Oklahoma, and Pennsylvania in Spring 2022, and in California in Winter 2022, it will feature all of these components, using facility-level data collected in each state. In the interim, the ATLAS team will be working with stakeholders and partners in each of the eleven states to collect data from addiction treatment providers, analyze and validate these data using industry best practices, and disseminate technical assistance resources to providers. Shatterproof partnered with key thought leaders and subject matter experts in the addiction treatment space to create ATLAS. The platform is based on quality measurement system best practices and uses metrics developed via a multi-step process, culminating with a National Quality Forum (NQF) expert panel and public comment period. Shatterproof continues to revise and update the ATLAS measures displayed on the platform to ensure they reflect current evidence in the field. ATLAS is funded by Arnold Ventures; the Duke Endowment; the Longwood Foundation; state partners: the California Department of Health Care Services, the Louisiana Department of Health, the Massachusetts Bureau of Substance Addiction Services, the New York State Office of Addiction Services and Supports, the Oklahoma Department of Mental Health and Substance Abuse Services, the Pennsylvania Department of Drug and Alcohol Programs, and the West Virginia Department of Health & Human Resources – Office of Drug Control Policy; and several national and state-based health care companies: Aetna, a CVS Health Company, Blue Cross and Blue Shield of North Carolina, Cigna, GuideWell in partnership with New Directions Behavioral Health, Horizon Blue Cross Blue Shield of New Jersey, and UnitedHealth Group. ### About Shatterproof: Shatterproof is a national nonprofit organization dedicated to reversing the addiction crisis in the United States. Shatterproof harnesses the models of business, the rigor of science and the power of a national movement to create change and save lives through three pillars of work: revolutionizing the addiction treatment system, breaking down addiction-related stigmas and supporting and empowering our communities. To learn more visit www.Shatterproof.org. Contact Details Holly Jespersen +1 646-334-1024 hjespersen@shatterproof.org Company Website https://www.shatterproof.org/

July 21, 2021 09:03 AM Eastern Daylight Time

Article thumbnail News Release

NEW STUDY SHOWS NOVEL PERSONALIZED SYSTEMS NUTRITION PROGRAM IMPROVES DIETARY PATTERNS, LIFESTYLE BEHAVIORS AND HEALTH-RELATED OUTCOMES

Nlumn

The Habit PATH (Personalized Approaches To Health) Study demonstrates that a Personalized Systems Nutrition program in a workforce environment improves dietary habits, health markers, physical activity and other health-related outcomes. The Habit PATH Study helps validate a holistic approach to personal nutrition that: Introduces a new approach that customizes nutrition systems according to an individual’s phenotypic flexibility assessment, which measures health according to their ability to adapt to a temporary nutritional stressor or an environmental challenge. This technology can identify potential health concerns to allow for early intervention and treatment. Provides personal goal setting and motivational interviewing to affect behavioral change and improve an individual’s adherence to lifestyle intervention programs. The Habit PATH Study suggests that personalized nutrition programs may provide the tools and motivation to enable individuals to meet their unique needs, achieve public health recommendations and improve health-related outcomes that may help reduce the health economic burden of chronic disease. Nlumn, LLC, a personalized nutrition and health company, announced health outcomes from a study of a novel Personalized Systems Nutrition program in the June 2021 issue of Nutrients. The peer-reviewed Habit PATH Study is the first to incorporate phenotypic flexibility technology in Personalized Systems Nutrition programs to improve the dietary patterns, lifestyle behaviors and health-related outcomes of individuals in a workplace environment. “The Habit PATH Study shows that personalized science-based nutrition and behavior interventions have the potential to improve overall diet quality and health markers that could reduce the chronic disease burden and improve the overall state of health in the United States,” said Josh Anthony, Ph.D., Founder and CEO, Nlumn and co-author of the study. “The results suggest that a systems-based personalized nutrition approach, combining both biological and behavioral science, not only helps address an individual’s unique health needs, but also helps them achieve public health recommendations, including the Dietary Guidelines for Americans. Consequently, personalized approaches may be more effective in motivating people to achieve public health recommendations compared to general guidelines.” Participants saw health changes that were consistent with public health recommendations including: Saturated fat intake was reduced more than 20%. Total sugar and sodium intake were reduced by almost 20%. These changes are consistent with the 2020-2025 Dietary Guidelines Key Recommendations to limit specific nutrients. Key nutrients such as potassium, fiber, magnesium, vitamin C and beta carotene increased, suggesting increased intake of fruit and vegetables. While this was not designed to be a weight loss study, caloric intake decreased 13% and participants saw reduced body weight, BMI, hip circumference and a reduction in body fat. Physical activity also increased. The most unhealthy participants reported a 10% reduction in total cholesterol and a 15% decrease in LDL (bad) cholesterol. “This study shows that assessing health status by using phenotypic flexibility to direct personal nutrition recommendations enables positive lifestyle changes and health outcomes regardless of an individual’s level of health,” according to Iris M. de Hoogh, scientist, Netherlands Organization for Applied Scientific Research (TNO) and lead author of the study. “The application of TNO’s Phenotypic Flexibility Technology helps identify early health interventions that individuals can address with their healthcare professionals before the health concern becomes a significant issue.” Anthony continued, “At a time when the U.S. is facing a multidimensional, multigenerational health crisis, and consumer demand for more nutritious food is at an all-time high, this study also helps verify the ability to use personalized subcategories to tailor food and product innovation pipelines in a meaningful way – thereby increasing the potential for long-term positive health benefits from personalized nutrition for food and insurance companies.” As part of this study, Personalized Systems Nutrition algorithms provided the employer’s food service partner with recommendations used to tailor breakfast and lunch options to align with study participants’ individual health needs. HABIT Study Results: Results of the study show that personalized nutrition programs are more effective for improving diet quality, supporting improved health-outcomes and may enable healthier lifestyle behaviors, particularly among individuals who have compromised phenotypic flexibility, a measure of the body’s ability to adapt to nutritional or environmental stressors, such as physical exercise, infections or mental stress. During the HABIT Study 10-week personalized intervention, participants showed statistically significant results: Dietary Indicators: Notable dietary improvements were observed between the intervention. Including a decrease in total and saturated fat, sugar and sodium, while showing improvements in vitamin C, magnesium, potassium, and beta carotene intake, suggesting a higher intake of fruits and vegetables. Notes: 73 participants were included in the per protocol analysis. Health Indicators: During the intervention, participants received personalized dietary recommendations, coaching and personalized meals. Several health improvements were observed for the overall study population. While this was not designed to be a weight loss trial, BMI (-0.6 kg/m2; p<0.0001), body fat (-1.2%, p=0.0192) and hip circumference (-5.8 cm; p<0.0001) showed a significant decrease. Subgroup Results: In reporting health measurements, the Habit Study’s automated Personalized Systems Nutrition algorithms assigned individuals to different subgroups based on their metabolic health status determined by phenotypic flexibility assessment at baseline. Groups A (n=48) and G (n=22) represented the most and least phenotypically flexible groups, respectively. Group G had a higher degree of adiposity, and a higher age than group A. However, there were no differences in baseline dietary intake and both groups were 82% compliant with personalized meal intake. Clinical Chemistry (fasting): For group G, significant reductions in total cholesterol and LDL (“bad”) cholesterol were seen during the intervention. There were 48 and 22 subjects in groups A and G, respectively. *p<0.01, **p<0.0001 Subgroup differences during the 10-week intervention. Anthropometrics: During the intervention period, body weight significantly decreased in both group A (most healthy) and group G (least healthy). Notes: At baseline, BMI, body weight, body fat, waist circumference and hip circumference were greater in group G compared to group A. Percentages were used to normalize differences between groups, but absolute changes were proportionately greater in group G given higher starting values. Statistically significant differences are noted in the last two columns for changes in the groups A or G respectively and in the first column for changes in the per protocol study population; (*p<0.05; **p<0.001; ****p<0.0001). Subgroup population size may have limited the ability to detect differences in some measures that were observed in the overall study (per protocol) population. Dietary Indicators: When looking at subgroups A and G, the Personalized Systems Nutrition program not only improved adherence with population-based dietary guidelines, but also achieved better alignment with individual recommendations. For the unhealthiest group, G, different positive effects were seen with respect to dietary intake, consistent with their respective dietary recommendations. Protein and beta carotene intake increased in group G, but not in group A. The increase in protein intake can be directly related to the personalized advice for group G as they were recommended to consume a diet higher in protein relative to group A. The increase in beta carotene could be the result of a higher intake of fruits and vegetables. The results suggest that personalized nutrition programs may be more effective in motivating people to consume a diet that meets individual needs while moving them closer to public health recommendations overall. As such, personalized nutrition programs have added value as compared to general guidelines or one-size fits all recommendations. Physical Activity: The intervention resulted in an increase in physical activity within the study participants of more than 700 steps per day. This was accompanied by a small decrease in resting heart rate which could indicate improved physical fitness. This increase is interesting, since the intervention consisted only of dietary advice and participants did not receive recommendations on physical exercise. The increase in physical activity may be a beneficial side-effect of participating in a Personalized Systems Nutrition program. HABIT Study Trial Design The Habit Study enrolled 107 healthy men and women, aged 30 to 65 years of age, with a body mass index between 18.5 to 39.9 kg/m2, and who were recruited from a single workforce location. The intervention grouped individuals into seven diet types and created personalized recommendations based on their phenotypic, genotypic and behavioral data. The HABIT study was a single-arm, multi-phased, open-label exploratory trial designed to measure the effectiveness of personalized nutrition on changing lifestyle behaviors and health outcomes during four intervention periods. These four periods were classified as: Baseline (week 0) and run-in (week 0 - 10) Intervention Phase 1 (week 10 - 20) Intervention Phase 2 personalized coaching/advice (week 20 - 30) Follow-up (week 30 - 40) endpoint visit only. The publication focuses on the baseline through intervention Phase 1. As part of the study, participants received: An At-Home Phenotypic Flexibility Test and Sample Collection for collecting buccal cells, a series of three dried blood spots (DBS) and DNA (baseline only) samples. A Personalized Systems Nutrition Program designed by using individual on-boarding data, clinical measures and single nucleotide polymorphism (SNP) variants. Micronutrient recommendations were determined using onboarding, anthropometric and clinical measures. In addition, participants were provided with personalized recipes and meals according to their macro- and micronutrient recommendations. Three personalized coaching sessions by registered dietitian nutritionists (RDN) who were trained on coaching techniques and the algorithms supporting the Personalized Systems Nutrition system. These RDNs provided food and diet recommendations, helped motivated participants and coached them in setting and achieving personal goals. Study meals and compliance diaries. Starting at week 10, participants received tailored breakfast and lunch five days a week for nine weeks. Activity measurement. At the start of the trial, each participant was given a Fitbit® to measure and record their activity level. Approximately every five weeks participants would visit the study center to be tested and have data collected on: Clinical markers: Regular laboratory tests were conducted to track total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, glucose, C-peptide, and the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) and Matsuda indices measuring whole body insulin sensitivity. Dietary Intake: Using a standard dietary record methodology, participants tracked their food and beverages consumed for three days (two weekdays and one weekend day) prior to all visits. Anthropometrics and Vitals: During each visit, anthropometrics--height (first visit only), weight, fat mass, waist and hip circumference--and blood pressure were measured. Wellbeing and Lifestyle: Participants’ dietary behavior was assessed using the 34-item Adult Eating Behaviors Questionnaire and their Quality of Life using the 26-item World Health Organization Quality of Life (WHOQOL) questionnaire. Their daily activity and sleep were tracked with a Fitbit Charge 2 which monitored heart rate, number of steps and sleeping hours. About Personalized Systems Nutrition Personalized Nutrition is the use of individual-specific information, founded in evidence-based science, to promote dietary behavior change that may result in measurable health benefits. Personalized Systems Nutrition incorporates novel Phenotypic Flexibility Technology that customizes diets according to an individual’s phenotypic flexibility allowing them to measure their health according to their biological system’s ability to adapt to conditions of temporary stressors, such as a nutrition challenge, physical exercise, infections or mental stress. This technology helps identify potential early health interventions that individuals can address with their healthcare professionals before it becomes a significant health issue. By combining systems-based approaches to understanding a person’s biology and behavior science, Personalized Systems Nutrition programs are able to create significant and sustainable changes in a person’s health and wellness. About Nlumn Nlumn works with food, nutrition and health-based companies to translate nutrition science and technology to create new opportunities across the personalized nutrition marketplace. Our international, multidisciplinary team guides partners through all phases of strategy and development to accelerate the pace of innovation, from discovery to commercialization. Our mission is to make personalized nutrition accessible to help every individual make better choices and live a healthier life. For more information, visit www.nlumn.com. About TNO TNO (Netherlands Organization for Applied Scientific Research) is a not-for-profit research organization with the mission to connect people and knowledge to create innovations that boost the competitive strength of industry and the well-being of society in a sustainable way. TNO’s Healthy Living unit develops social and technological innovations to help people lead healthier lives and reduce lifestyle-related chronic diseases. TNO developed the phenotypic flexibility technology that was instrumental in the Habit PATH study. For more information, visit https://www.tno.nl/en/focus-areas/healthy-living/. Contact Details AgTech PR for Nlumn Jennifer Goldston +1 816-260-0040 jennifer@agtechpr.com

July 21, 2021 09:00 AM Eastern Daylight Time

Article thumbnail News Release

Kadimastem Patent for cell selection of beta cells to Treat and Potentially Cure Diabetes was Granted in Japan

Kadimastem LTD

Cell therapy company Kadimastem Ltd ( TASE: KDST ) has received its patent approval from the Japanese Patent Office for IsletRx, the company’s innovative treatment for diabetes. IsletRx comprises an expanded population of clinical grade pancreatic islet-like cluster (ILCs) cells, derived from human stem cells, that have the ability to secrete insulin when blood sugar is low and glucagon, a hormone secreted to prevent hypoglycemia, when blood sugar levels drop in response to varying sugar levels (glucose) in the blood. This particular function of IsletRX is similar to a "healthy" pancreas and functions to treat insulin-dependent diabetes, such as Type 1 diabetes also known as juvenile diabetes. The patent announced today protects Kadimastem’s cell selection and enrichment technology, that enables it to identify and fortify the best cells in the expanded population. The patent also covers the use of the company’s special production process, where it can remove cells that are not necessary or may impair the efficiency of the transplanted cells. These capabilities are important in achieving the maximum therapeutic effect for potential future insulin-dependent diabetic patients. In addition, this method of production and cell selection enables the ILCs to be transplanted using a variety of platforms, including very small devices that are more suitable and more convenient for patients. Kadimastem CEO Asaf Shiloni said, “Receiving the patent in Japan further strengthens our intellectual property position. The market, in Southeast Asia in general, and the Japanese market, are large and important for the company's future products. Registering the patent in Japan gives Kadimastem a much-welcomed priority status in this territory. We look forward to further developing business collaborations with key players in the pharmaceutical industry in Japan, both for our diabetes and ALS products.” The Japanese market is one of the most significant markets for stem cell-derived cell therapies. In Japan, 7.9% of the population is diabetic and there are more than 2.7 million insulin-dependent diabetic patients. Treatment of these patients is currently estimated at $ 29 billion. Japan has strategic importance in the field of stem cell therapy, as it is one of the world's most prominent countries in promoting innovation and products in the field of cell therapy. In November 2014, the Japanese Parliament approved a special law to facilitate clinical trials in the field of cellular medicine, with the aim of expediting approvals of intracellular therapies and quickly bringing them to market. Social Media: LinkedIn, Twitter, Facebook Company Contacts: Asaf Shiloni CEO a.shiloni@kadimastem.com Press Contact: Marjie Hadad General Manager Must Have Communications 917-790-1178 marjie@mhc-pr.com About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. Kadimastem is focusing on two promising products, AstroRx® and IsletRX. AstroRx®, the Company's clinically advanced product, is an astrocyte cell therapy in clinical development as a treatment for ALS and other neurodegenerative diseases. IsletRx, is comprised of functional Stem Cell derived pancreatic islet cells intended to cure patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in preclinical studies. Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Asaf Shiloni +972 73-797-1613 s.herzl@kadimastem.com Company Website https://www.kadimastem.com/

July 21, 2021 09:00 AM Eastern Daylight Time

1 ... 260261262263264 ... 302